Abstract:4003 1 alpha, 25-dihydroxy vitamin D 3 (1,25(OH) 2 D 3 ) demonstrates strong antiproliferative effects in a variety of cancer cell types including prostate cells while the PI3K/AKT pathway presents a pro-survival pathway implicated in prostate cancer. The antiproliferative effect of 1,25(OH) 2 D 3 almost universally involves upregulation of p21 and/or p27, while loss of PTEN and activation of PI3K/AKT can downregulate p21 and p27 levels by a number of mechanisms. We hypothesized that 1,25(OH) 2 D 3 signaling is antagonized by PI3K/AKT signaling. To test this we isolated Pten WT mouse prostatic epithelial cells (MPECs) from Pten floxed, Cre-negative mouse prostates and Pten null MPECs from the Pten lox/lox prostates where Pten was deleted by probasin-driven Cre-recombinase. We found that while Pten WT MPECs were significantly growth-inhibited by 1,25(OH) 2 D 3 , Pten null MPECs were completely unresponsive to 1,25(OH) 2 D 3 . By shRNA knockdown and by in vitro knockout of Pten in WT MPECs we then showed that Pten loss itself is insufficient to antagonize 1,25(OH) 2 D 3 -mediated growth suppression. To evaluate the ability of PI3K/AKT to antagonize 1,25(OH) 2 D 3 -mediated growth inhibition we used an inhibitor of PI3K/AKT - LY294002 and an inhibitor of AKT - SH-5. Pre-treatment of insensitive Pten-/- MPECs with LY294002 or SH-5 partially restored the sensitivity to and synergized with the antiproliferative actions of 1,25(OH) 2 D 3 . We extended the study to the human prostate cancer cell line LNCaP which is only moderately responsive to 1,25(OH) 2 D 3 . LY294002 and 1,25(OH) 2 D 3 treatment demonstrated statistically significant synergistic inhibition of LNCaP cell growth (CI=0.171 at 0.2μM LY294002 and 1nM 1,25(OH) 2 D 3 ). Interestingly, LY294002 sensitized DU145 cells to 1,25(OH)2 D3, a cell line that is insensitive to 1,25(OH) 2 D 3 -mediated growth inhibition, leading to a strong statistically significant synergism. While neither 2.5μM LY294002 nor 10nM 1,25(OH) 2 D 3 affected the growth of DU145 cells, the combination of the two led to a 40% reduction in the number of viable cells. Rapamycin did not synergize with 1,25(OH) 2 D 3 in the growth inhibition suggesting that the mTOR pathway is not involved in the mechanism. Immunoblot analysis showed that 1,25(OH) 2 D 3 alone was able to decrease AKT phosphorylation in prostate cancer cells. In DU145 cells LY294002 and 1,25(OH) 2 D 3 cooperatively inhibited the phosphorylation of AKT. Taken together we conclude that inhibition of the PI3K/AKT pathway synergizes with the antiproliferative actions of 1,25(OH) 2 D 3 in prostate cancer cell lines possibly by additive reduction of AKT phosphorylation. The findings from the present study provide the rationale for the development of improved combinational therapeutic interventions utilizing 1,25(OH) 2 D 3 or its analogs combined with inhibition of PI3K/AKT for the treatment of prostate cancer.

Without 1α-hydroxylation, the gene expression profile of 25(OH)D3 treatment overlaps deeply with that of 1,25(OH)2D3 in prostate cancer cells

Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells

Effects Of 1 Alpha,25 Dihydroxyvitamin D3 And Testosterone On Mirna And Mrna Expression In Lncap Cells

Vitamin D, Intermediary Metabolism and Prostate Cancer Tumor Progression

Vitamin D-3 Modulated Gene Expression Patterns In Human Primary Normal And Cancer Prostate Cells

Interleukin-1α Mediates the Antiproliferative Effects of 1,25-Dihydroxyvitamin D3 in Prostate Progenitor/stem Cells.

1 Alpha,25-Dihydroxyvitamin D (calcitriol) Inhibits the Invasiveness of Human Prostate Cancer Cells.

226 THE PROGNOSTIC SIGNIFICANCE OF PREOPERATIVE SERUM LEVELS OF EXTRACELLULAR MATRIX PROTEIN 1 IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

1,25-Dihydroxyvitamin D3 Suppresses Prognostic Survival Biomarkers Associated with Cell Cycle and Actin Organization in a Non-Malignant African American Prostate Cell Line

Progress in Effects of VDR Variant Mediated Transcriptional Regulation on Its Downstream Target Gene

Dissection of an impact of VDR and RXRA on the genomic activity of 1,25(OH)2D3 in A431 squamous cell carcinoma

1,25-dihydroxyvitamin D3 inhibits phosphorylation of AKT and synergizes with pharmacological PI3K/AKT inhibitors to suppress prostate cancer cell growth

20-Hydroxyvitamin D2 is a Noncalcemic Analog of Vitamin D with Potent Antiproliferative and Prodifferentiation Activities in Normal and Malignant Cells.

Induction Of Differentiation By 1 Alpha-Hydroxyvitamin D-5 In T47d Human Breast Cancer Cells And Its Interaction With Vitamin D Receptors

Gene Expression Profiling of 1α,25(OH)2 D3 Treatment in 2D/3D Human Hepatocyte Models Reveals CYP3A4 Induction but Minor Changes in Other Xenobiotic-Metabolizing Genes

1,25-Dihydroxyvitamin D-3 Up-Regulates Expression of Hsa-Let-7a-2 Through the Interaction of Vdr/Vdre in Human Lung Cancer A549 Cells

Trichostatin A and Genistein Enhance the Anti-proliferative Effect of Vitamin D on Prostate Cancer Cells

Vitamin D Receptor Protein Expression in Tumor Tissue and Prostate Cancer Progression

20-hydroxyvitamin D₃ inhibits proliferation of cancer cells with high efficacy while being non-toxic.

1Α,25(oh)2d3 Reverses Exhaustion and Enhances Antitumor Immunity of Human Cytotoxic T Cells.

1Α,25(oh) 2D 3 Decreases Expression of Immune Checkpoint Receptors and Enhances Anti-Tumor Immunity of Human Cytotoxic T Cells